I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma Journal Article

Authors: Carrasquillo, J. A.; O'Donoghue, J. A.; Beylergil, V.; Ruan, S.; Pandit-Taskar, N.; Larson, S. M.; Smith-Jones, P. M.; Lyashchenko, S. K.; Ohishi, N.; Ohtomo, T.; Abou-Alfa, G. K.
Article Title: I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma
Abstract: Background: I-124 codrituzumab (aka GC33), an antibody directed at Glypican 3, was evaluated in patients with hepatocellular carcinoma (HCC). Fourteen patients with HCC underwent baseline imaging with I-124 codrituzumab (~ 185 MBq, 10 mg). Seven of these patients undergoing sorafenib/immunotherapy with 2.5 or 5 mg/kg of cold codrituzumab had repeat imaging, with co-infusion of I-124 codrituzumab, as part of their immunotherapy treatment. Three patients who progressed while on sorafenib/immunotherapy were re-imaged after a 4-week washout period to assess for the presence of antigen. Serial positron emission tomography (PET) imaging and pharmacokinetics were performed following I-124 codrituzumab. An ELISA assay was used to determine “cold” codrituzumab serum pharmacokinetics and compare it to that of I-124 codrituzumab. Correlation of imaging results was performed with IHC. Short-term safety assessment was also evaluated. Results: Thirteen patients had tumor localization on baseline I-124 codrituzumab; heterogeneity in tumor uptake was noted. In three patients undergoing repeat imaging while on immunotherapy/sorafenib, evidence of decreased I-124 codrituzumab uptake was noted. All three patients who underwent imaging after progression while on immunotherapy continued to have I-124 codrituzumab tumor uptake. Pharmacokinetics of I-124 codrituzumab was similar to that of other intact IgG. No significant adverse events were observed related to the I-124 codrituzumab. Conclusions: I-124 codrituzumab detected tumor localization in most patients with HCC. Pharmacokinetics was similar to that of other intact iodinated humanized IgG. No visible cross-reactivity with normal organs was observed. © 2018, The Author(s).
Keywords: antibody; i-124; hepatocellular; glypican; codrituzumab
Journal Title: EJNMMI Research
Volume: 8
ISSN: 2191-219X
Publisher: Springer  
Date Published: 2018-03-05
Start Page: 20
Language: English
DOI: 10.1186/s13550-018-0374-8
PROVIDER: scopus
PMCID: PMC5838028
PUBMED: 29508107
Notes: Article -- Export Date: 2 April 2018 -- Source: Scopus
Altmetric Score